Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PPP5C | P53041 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13083168 | 1.00 | GBA1 (0.44) | GBA1SMN1; SMN2PPP5CSPHK2SPHK1 | |
| SCHEMBL16508369 | 1.00 | GBA1 (0.44) | GBA1SMN1; SMN2PPP5CSPHK2SPHK1 | |
| SCHEMBL16248055 | 1.00 | GBA1 (0.44) | GBA1SMN1; SMN2PPP5CSPHK2SPHK1 | |
| SCHEMBL12817866 | 0.88 | GBA1 (0.42) | GBA1SMN1; SMN2PPP5CSPHK2SPHK1 | |
| SCHEMBL18102895 | 0.85 | GBA1 (0.43) | GBA1SMN1; SMN2PPP5CSPHK2SPHK1 | |
| SCHEMBL11097329 | 0.85 | GBA1 (0.46) | GBA1SMN1; SMN2SPHK2SPHK1 | |
| SCHEMBL2044382 | 0.85 | GBA1 (0.46) | GBA1SMN1; SMN2SPHK2SPHK1 | |
| SCHEMBL14554178 | 0.83 | GBA1 (0.41) | GBA1SMN1; SMN2SPHK2SPHK1 | |
| SCHEMBL13665027 | 0.83 | GBA1 (0.41) | GBA1SMN1; SMN2PPP5CSPHK2SPHK1 | |
| SCHEMBL3960989 | 0.80 | GBA1 (0.53) | GBA1SPHK2SPHK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130011421-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011421-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | LSS, CYP51A1, TLR7 | GBA1 261/4885SMN1; SMN2 4439/4885PPP5C 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.